Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;134(1):95-101.
doi: 10.1017/S095026880500470X.

Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania

L A Kondili  1 , P Chionne, A Porcaro, E Madonna, S Taffon, B Resuli, G Taliani, M Rapicetta
Affiliations

Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania

L A Kondili et al. Epidemiol Infect. 2006 Feb.

Abstract

A case-control study involving 109 in-patients with chronic liver disease and 190 in-patients with no apparent liver disease was conducted to evaluate the seroprevalence of anti-HEV antibodies and the possible association with chronic liver disease. Among cases, the anti-HEV prevalence was 36.6% which increased significantly by age; among controls, the prevalence was 12.1% (P<0.05) and was similar among age groups <60 years. Among cases, aged >50 years (OR 4.0, 95% CI 1.4-11) and the presence of end stage liver disease (ESLD) (OR 4.3, 95% CI 1.4-12.8) were associated independently with anti-HEV positivity. The mean optical density, determined by anti-HEV immunoenzymatic test, was significantly higher among patients with ESLD, compared to the other patients. These results indicate that there is a high seroprevalence of anti-HEV in patients with chronic liver disease and a possible association between HEV infection and/or anti-HEV production and advanced stage chronic liver disease.

PubMed Disclaimer

Figures

Fig
Fig
Age-specific prevalence of anti-HEV in 109 patients with chronic liver disease (▪, cases) and 190 patients with no apparent liver disease (□, controls).
See this image and copyright information in PMC

References

    1. Paul DA, Knigge MF, Ritter A et al. Determination of hepatitis E virus seroprevalence by using recombinant fusion proteins and synthetic peptides. J Infect Dis. 1994;169:801–806. - PubMed
    1. Balayan MS. Epidemiology of hepatitis E virus infection. J Viral Hepat. 1997;4:155–165. - PubMed
    1. Center for Disease Control and Prevention. Hepatitis E among U.S. travelers, 1989–1992. Morb Mortal Wkly Rep. 1993;42:1–4. - PubMed
    1. De Cock KM, Bradley DW, Sandford NL et al. Epidemic non-A, non-B hepatitis in patients from Pakistan. Ann Intern Med. 1987;106:227–230. - PubMed
    1. Zanetti AR, Dawson GJ. Hepatitis type E in Italy: a seroepidemiological survey. Study Group of hepatitis E. J Med Virol. 1994;42:318–320. - PubMed

Publication types

Substances